Chair: Peter Greenleaf, Chief Executive Officer, Sucampo
Staff Contacts: Frederick Bittenbender, Executive Vice President, Public Affairs, firstname.lastname@example.org
Subject Matter/Jurisdiction: The committee provides strategic oversight of membership-related issues, offering guidance and recommendations on various activities, including but not limited to, dues structure (potential dues increases and/or restructuring); membership for non-innovative companies; the development of a strategic membership plan; and the enhancement of member services and related resources.
Peter Greenleaf, Chief Executive Officer, Sucampo Pharmaceuticals
Ron Cohen, President & CEO, Acorda Therapeutics Inc.
Paul Hastings, President & CEO, OncoMed Pharmaceuticals Inc.
Hervé Hoppenot, President & CEO, Incyte Corporation
John Johnson, CEO & President, Dendreon Corporation
Robert Kiss, Portfolio Manager, JP Morgan Asset Management
John Maraganore, Chief Executive Officer. Alnylam Pharmaceuticals Inc.
Steven Mento, President& CEO, Co-Founder and Chairman, Conatus Pharmaceuticals, Inc.
John Orwin, Chief Executive Officer, Relypsa Inc.
Kristine Peterson, Chief Executive Officer, Valeritas Inc.
David Pyott, Chairman President & CEO, Allergan Inc
Timothy Rodell, Chief Executive Officer & President, GlobeImmune, Inc.
Ronald Stotish, Chief Executive Officer, Aqua Bounty Technologies, Inc.
Daniel Tassé, Chairman & CEO, Ikaria, Inc.
Timothy Walbert, Chairman President & CEO, Horizon Pharma Inc